Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 89 for “"BRAF"”.
-
Epigenetic Modulation In Braf Mutated Metastatic Colorectal Cancer
<p><strong>Introduction:</strong> BRAF V600E mutations are associated with poor clinical outcomes for patients with metastatic colorectal cancer (mCRC). Unlike other tumors with the same mutation, BRAF inhibitors are ineffective as monotherapy. CRC tumors with BRAF V600E mutations are associated …
-
Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma
… selective pressure to engage any of the many BRAF-independent ERK1/2 pathway activation mechanisms. By integration of multi-genome chemical and genetic screens; recurrent architectural variants in melanoma tumor genomes; and patient outcome data; we identified 2 mechanistic subtypes of …
-
Roles For Braf Kinase Activating Mutations In Melanoma: Microenvironmental Immunosuppression
<p>The BRAF oncogene demonstrates a characteristic mutation (V600E) in a significant fraction of cutaneous melanomas, leading to constitutive activation of the MAP kinase pathway. This genetic lesion endows tumor cells with proliferative and survival advantages, and metastatic melanoma patients …
-
Assessing the Mutational Landscape of BRAF- and KRAS-Wild Type Colorectal Cancer
… are driven by activating mutations in KRAS or BRAF oncogenes. However, the other 50% of colorectal cancer cases are wild type for both genes; thus identification and characterization of the landscape of mutations in non-BRAF and KRAS-mutated colorectal cancer is helpful to propose suitable …
-
Optimization of BRAF V600 Assay as A 2-Step Real-time PCR Protocol
<p>The QClamp® BRAF Codon Specific Mutation Detection Kit is a real-time PCR assay for the detection of somatic mutations in codon 600 Valine at exon 15 in the BRAF gene which encodes the serine/threonine protein kinase, using purified DNA. The V600E mutation is the most common BRAF gene mutation …
-
A NOVEL BRAF SIGNALING CASCADE THROUGH p-21 ACTIVATED KINASES REGULATES THYROID CANCER CELL MOTILITY
… is the presence of the activating mutation BRAF V600E. From our prior studies, we determined that the invasive fronts of aggressive PTC exhibited a characteristic change in morphology known as epithelial-to-mesenchymal transition (EMT). EMT has been linked to aggressive or late stage tumor …
-
Investigation of signalling pathways associated with the development of BRAF inhibitor resistance and treatment of melanoma
… It is the fifth most common cancer in UK. BRAF V600E mutation is observed in approximately 50% of melanomas and causes excessive stimulation of the MAPK signalling leading to proliferation, metastasis and invasion. In BRAF V600E positive mela-noma patients, BRAF is inhibited to prevent MAPK …
-
Epigenetic Modification as a Therapeutic Target in BRAFV600E-mutated Metastatic Colorectal Cancer
<p>Patients with BRAF<sup>V600E</sup>-mutated metastatic colorectal cancer (mCRC) experience a worse prognosis and demonstrate only a 5% response rate to BRAF inhibitor treatment. In this study, adaptive resistance, and a potential combination of standard therapies in BRAF<sup>V600E</sup> CRC were …
-
Functional assessment of BRAF and CRAF through Base Editor 3 mutagenesis reveals residues and regions critical for ERK1/2 signalling
… RASopathies. Therapeutic targeting of class I BRAF mutants has proven successful but BRAF inhibitors have failed in cancers with wild type RAF because sub-saturating doses of inhibitors drive paradoxical activation of wild-type RAF. Base editor 3 (BE3) is a gene editing tool comprised of a …
-
An investigation on role of the ATP-binding cassette B5 (ABCB5) transporter as potential mediator of melanoma resistance to BRAF inhibition
… deaths. Targeted therapies, in the form of BRAF inhibitors (BRAFis), have been effective at treating BRAFV600 mutant melanomas. However, majority of the melanoma patients fail to respond to BRAFis due to intrinsic or acquired resistance within one year of treatment commencement. Multiple …
-
Overcoming Acquired Resistance to BRAF Inhibitors by Novel Synergistic Drug Combination and Discovery of Novel Smac Mimetics as Selective Survivin Inhibitors
… clinical resistance to vemurafenib, a selective BRAFV600E inhibitor, arises frequently after short term chemotherapy. Since the inhibitions of targets in the RAFMEK-ERK pathway result in G0/G1 cell cycle arrest, vemurafenib-resistant cancer cells are expected to escape this cell cycle arrest and …
-
Impacto de la mutación en KRAS y BRAF en los resultados de carcinoma colorrectal metastásico: análisis retrospectivo de un estudio multicéntrico
Introducción: Las alteraciones en la vía de señalización de las proteínas cinasas activadas por mitógenos (MAPK), esenciales en el desarrollo del cáncer colorrectal metastásico (CCRm), inducen variaciones dinámicas y temporales que a menudo se subestiman en los ensayos clínicos. Este trabajo …
-
Comparative Morphological and Immunohistochemical Analysis of Benign and Malignant Epithelial Colon Tumors // Сравнителен морфологичен и имунохистохимичен анализ на бенигнени и малигнени епителни тумори на дебелото черво
… експресия на протеини APC, p53, SMAD4, MSH2 и BRAF при доброкачествени и злокачествени епителни тумори на дебелото черво във връзка с клинико-морфологичните показатели и ролята им в туморната инициация и прогресия. Получихме следните резултати: с редуциране площта на експресия на АРС намалява …
-
A Phase I Dose-Escalation Study of The Braf Inhibitor Vemurafenib In Combination With The Mtor Inhibitor Everolimus In Subjects With Advanced Cancer
… for the treatment of relapsed or refractory BRAF mutation positive malignant melanoma and is being investigated in various other malignancies. The RAS/RAF/MEK/ERK (MAPK) pathway is critical to cell proliferation in many human cancers. The mTOR inhibitors are well known to exert profound …
-
The relationship between BRAF genetic alterations and the risk of tumour recurrence in Pilocytic Astrocytomas in children diagnosed at Red Cross Children's Hospital over a 33-year period
… of the MAPK signalling pathway, with BRAF gene mutations being the most frequent. 4 However, reports on the impact of specific mutations on patient prognosis are controversial. 5–8 Advances in molecular techniques have opened the door for further studies to determine the relationship …
-
Juvenile pilocytic astrocytomas: A search for prognostic markers
… microscopic features and also evaluating the BRAF, p16 and protein kinase ERK components of the MAPK pathway. The findings thereof were correlated with the clinical picture to establish if these markers have any prognostic or predictive value. Materials and methods: The total number of cases …
Page 1 of 5